Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and antigenicity of FBS-free/HSA-free Rebif in relapsing multiple sclerosis
2004-003799-13Phase 3Completed
- Sponsor
- Serono
- Start
- Dec 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Serono. Primary endpoint: Proportion of subjects neutralizing antibody positive at Week 96. Started Dec 2004; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2004-003799-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003799-13.